{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:45Z","timestamp":1787026665073,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Anti-CD38 antibodies such as daratumumab (DARA) and isatuximab (ISA), used in multiple myeloma (MM) therapy, bind to CD38 on red blood cells (RBCs), leading to pan-agglutination in indirect antiglobulin tests (IATs) and interfering with pretransfusion testing. Given the frequent need for transfusions in MM patients with anemia, resolving this interference is clinically essential. While dithiothreitol (DTT) is commonly used, it compromises clinically important RBC antigens. To address this limitation, a novel approach was developed using a recombinant rabbit anti-human CD38 IgG monoclonal antibody, D2, to treat RBCs. Rabbits were immunized with hCD38-His. Antigen-specific B cells were isolated via flow cytometry and subsequently sequenced to obtain the antibody genes. After cloning and expression, a rabbit mAb named D2 was selected for its ability to bind the CD38 on human RBCs and block the binding of therapeutic anti-CD38 antibodies without affecting other RBC blood group antigens. Incubation of 1 \u03bcL of packed RBCs with 3 \u03bcL of 1 mg\/mL D2 for 10 minutes at room temperature eliminated DARA- or ISA-induced pan-agglutination in the IAT while preserving the detection of clinically significant irregular antibodies. Its efficacy was confirmed using samples from 48 DARA- or ISA-treated patients. D2 is stable, easy to use, and suitable for routine application in transfusion laboratories to resolve anti-CD38-induced interference in pretransfusion testing.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1726341","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:29:13Z","timestamp":1770708553000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A rabbit anti-human CD38 antibody for eliminating daratumumab and isatuximab interference in immunohematology testing"],"prefix":"10.3389","volume":"17","author":[{"given":"Liangzi","family":"Zhang","sequence":"first","affiliation":[{"name":"Shaanxi Blood Center","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinze","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, Shenzhen University General Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qi","sequence":"additional","affiliation":[{"name":"Shaanxi Blood Center","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Su","sequence":"additional","affiliation":[{"name":"Shaanxi Blood Center","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Zuo","sequence":"additional","affiliation":[{"name":"Shaanxi Blood Center","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, The Affiliated Hospital of Northwest University, Xi\u2019an No.3 Hospital","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, The Second Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xu","sequence":"additional","affiliation":[{"name":"Shaanxi Blood Center","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13789","article-title":"International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing","volume":"56","author":"Chapuy","year":"2016","journal-title":"Transfusion"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01311-1","article-title":"Isatuximab: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102810","article-title":"New treatment strategies for igA nephropathy: targeting plasma cells as the main source of pathogenic antibodies","volume":"11","author":"Maixnerova","year":"2022","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029006","article-title":"Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia","volume":"145","author":"Gao","year":"2025","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2407009","article-title":"Felzartamab and antibody-mediated rejection in kidney transplants - hope at last","volume":"391","author":"Ingelfinger","year":"2024","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010077","article-title":"Is there a future for anti-CD38 antibody therapy in systemic autoimmune diseases","volume":"9","author":"Benfaremo","year":"2019","journal-title":"Cells"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","article-title":"Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member","volume":"160","author":"Deaglio","year":"1998","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.8235624","article-title":"Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38","volume":"262","author":"Howard","year":"1993","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R500012200","article-title":"Nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated calcium signaling","volume":"280","author":"Lee","year":"2005","journal-title":"J Biol Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483511","article-title":"Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity","volume":"122","author":"Cagnetta","year":"2013","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00305","article-title":"Roles and modalities of ectonucleotidases in remodeling the multiple myeloma niche","volume":"8","author":"Chillemi","year":"2017","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.10.12.8903511","article-title":"Human CD38, a cell-surface protein with multiple functions","volume":"10","author":"Mehta","year":"1996","journal-title":"FASEB J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02616","article-title":"Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies","volume":"9","author":"Lancman","year":"2018","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion"},{"key":"B21","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2017-0328","article-title":"EMA review of daratumumab for the treatment of adult patients with multiple myeloma","volume":"23","author":"Tzogani","year":"2018","journal-title":"Oncologist"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1983.00561.x-i1","article-title":"Disulfide bonds are a requirement for Kell and Cartwright (Yta) blood group antigen integrity","volume":"54","author":"Branch","year":"1983","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13707","article-title":"Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma","volume":"48","author":"Quach","year":"2018","journal-title":"Intern Med J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15341","article-title":"Manual polybrene method for pretransfusion test could overcome the interference of daratumumab therapy in myeloma","volume":"59","author":"Yeh","year":"2019","journal-title":"Transfusion"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15932","article-title":"Daudi cell stroma: An alternative to dithiothreitol to resolve daratumumab interference in pretransfusion testing","volume":"60","author":"Tremblay","year":"2020","journal-title":"Transfusion"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011396","article-title":"Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing","volume":"138","author":"Ehrend","year":"2021","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1056\/NEJMx180041","article-title":"F(ab\u2019)(2) fragments to overcome daratumumab interference in transfusion tests","volume":"380","author":"Selleng","year":"2019","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17253","article-title":"Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform","volume":"63","author":"Habicht","year":"2023","journal-title":"Transfusion"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15202","article-title":"A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing","volume":"59","author":"Chinoca Ziza","year":"2019","journal-title":"Transfusion"},{"key":"B31","volume-title":"\u00d6sterreichische Gesellschaft f\u00fcr Blutgruppenserologie, Regenerative Medizin und Immungenetik (\u00d6GBT), Empfehlungen f\u00fcr das pr\u00e4transfusionelle Vorgehen bei PatientInnen mit Anti-CD38-\/Daratumumab-Therapie, Version 3","year":"2019"},{"key":"B32","volume-title":"Judd\u2019s methods in immmunohematology","author":"Judd","year":"2022"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14900","article-title":"Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol\/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method)","volume":"58","author":"Hosokawa","year":"2018","journal-title":"Transfusion"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15305","article-title":"Additional validation of Osaka method (0.01\u2009mol\/L dithiothreitol) for negating the daratumumab interference","volume":"59","author":"Hosokawa","year":"2019","journal-title":"Transfusion"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17006","article-title":"Efficient neutralization of daratumumab in pretransfusion samples using a novel recombinant monoclonal anti-idiotype antibody","volume":"62","author":"Aung","year":"2022","journal-title":"Transfusion"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/tme.13139","article-title":"Antigen masking indirect antiglobulin test can mitigate the interference of Mezagitamab, a novel anti-CD38 antibody, in serological pre-transfusion testing","author":"Habicht","year":"2025","journal-title":"Transfus Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40262-023-01240-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of daratumumab","volume":"62","author":"Kim","year":"2023","journal-title":"Clin Pharmacokinet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1726341\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:21:00Z","timestamp":1771928460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1726341\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2026.1726341"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1726341","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"article-number":"1726341"}}